PMID- 7585656
OWN - NLM
STAT- MEDLINE
DCOM- 19951214
LR  - 20141120
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 55
IP  - 23
DP  - 1995 Dec 1
TI  - Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: 
      correlation with overall survival.
PG  - 5693-8
AB  - Few molecular genetic alterations have been identified in endometrial cancers 
      that are associated with poor clinical outcome. Overexpression of HER-2/neu, 
      transforming growth factor alpha, and p53 proteins have all been associated with 
      poor prognosis in women with endometrial cancer. In this study, the level of 
      HER-2/neu gene amplification and expression was characterized in 92 endometrial 
      cancers. Fluorescence in situ hybridization (FISH) was used to characterize 
      HER-2/neu gene copy number, and immunohistochemistry was used to characterize 
      expression. Forty-seven of the 90 (52%) endometrial cancers were characterized as 
      showing moderate or high immunostaining. HER-2/neu gene amplification was 
      detected in 17 of 81 (21%) cases. Immunohistochemical staining and FISH results 
      were both available for 80 cases. Fourteen of these cases showed both moderate or 
      high immunostaining and gene amplification. Clinical follow-up information was 
      available for 76 women in this study. Women whose endometrial cancer exhibited 
      HER-2/neu gene amplification by FISH had a shorter overall survival than women 
      whose endometrial cancer lacked amplification (P = 0.018). Likewise, tumors with 
      moderate or high HER-2/neu immunostaining were associated with a lower cumulative 
      overall survival than tumors with low immunostaining by log rank analysis (P < 
      0.0001). Multivariate analysis of survival rates revealed HER-2/neu 
      overexpression to be an independent predictor of overall survival (P = 0.0163). 
      Among those patients with HER-2/neu overexpression, adjuvant chemotherapy or 
      radiation therapy was associated with an improved overall survival (P = 0.039). 
      However, among those women whose tumor lacked overexpression, overall survival 
      was not improved by adjuvant treatment.
FAU - Saffari, B
AU  - Saffari B
AD  - Department of Pathology, University of Southern California School of Medicine, 
      Los Angeles 90033, USA.
FAU - Jones, L A
AU  - Jones LA
FAU - el-Naggar, A
AU  - el-Naggar A
FAU - Felix, J C
AU  - Felix JC
FAU - George, J
AU  - George J
FAU - Press, M F
AU  - Press MF
LA  - eng
GR  - CA48780/CA/NCI NIH HHS/United States
GR  - CA50589/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Endometrial Neoplasms/*genetics/*metabolism/pathology/therapy
MH  - Female
MH  - Gene Amplification/*genetics
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Retrospective Studies
EDAT- 1995/12/01 00:00
MHDA- 1995/12/01 00:01
CRDT- 1995/12/01 00:00
PHST- 1995/12/01 00:00 [pubmed]
PHST- 1995/12/01 00:01 [medline]
PHST- 1995/12/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1995 Dec 1;55(23):5693-8.